Partially offsetting this are declines in cardiovascular drug Xarelto due to loss of exclusivity events across various territories, which is putting pressure on both revenue growth and profit margins.

Your head hurts. Maybe you were staring at your computer or phone too long. Or you skipped breakfast, didn’t sleep well, or got stressed fighting traffic. But now that it’s here, what can you do to ...

In partnership with Liveo Research, Bayer has developed a 'first-of-its-kind' PET blister pack for its over-the-counter Aleve drug brand - and reports a 38% reduction in carbon footprint through its ...

Federal officials have celebrated a striking drop in drug overdoses across the country. But state-level data shows that Black people are suffering significantly worse outcomes than white people.

The U.S. Food and Drug Administration announced a Class II recall for more than 7,100 bottles of Duloxetine — a generic antidepressant for Cymbalta — due to a cancerous chemical. A voluntary ...

The U.S. Food and Drug Administration announced a Class II recall for more than 7,100 bottles of Duloxetine — a generic antidepressant for Cymbalta — due to a cancerous chemical. A voluntary ...

The drug Donanemab has been found to slow the progression of Alzheimer’s disease. Despite this is has been rejected for widespread use in the health service in England after the health spending ...

CIIMAR─Interdisciplinary Centre of Marine and Environmental Research, Endocrine Disruptors and Emerging Contaminants Group, University of Porto, Avenida General Norton de Matos, S/N, Matosinhos ...

On X recently, Eric Topol, a cardiologist who leads Scripps Research, a non-profit research institute in San Diego, California, called GLP-1 drugs “the most important drug-class breakthrough in ...

A pioneering new drug, which has been shown to slow the advance of Alzheimer's, will not be available to patients on the NHS as Ian Woods reports. A new "effective" Alzheimer's drug has been ...

For many patients on tirzepatide, a transformative medication used for weight loss and diabetes, the end of the drug's shortage was anything but welcome news. "I had an anxiety attack," said Maria ...

A second Alzheimer’s drug has been rejected for widespread use in the NHS in England after the health spending watchdog said that it “does not currently demonstrate value” for money.